Cannabinoid CB(1) Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors

An improved understanding of the endocannabinoid system has provided new avenues of drug discovery and development toward the management of pain and other behavioral maladies. Exogenous cannabinoid type 1 (CB(1)) receptor agonists such as Δ(9)-tetrahydrocannabinol are increasingly used for their med...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Pharmacol Exp Ther
Glavni autori: Leonard, Michael Z., Alapafuja, Shakiru O., Ji, Lipin, Shukla, Vidyanand G., Liu, Yingpeng, Nikas, Spyros P., Makriyannis, Alexandros, Bergman, Jack, Kangas, Brian D.
Format: Artigo
Jezik:Inglês
Izdano: The American Society for Pharmacology and Experimental Therapeutics 2017
Teme:
Behavioral Pharmacology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5683067/
https://ncbi.nlm.nih.gov/pubmed/28947487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.117.244392
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items